New drug cocktail shows promise for tough bile duct cancer
NCT ID NCT07619937
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tested a three-drug combination—chemotherapy infused into the liver, an immunotherapy drug (tislelizumab), and a targeted pill (regorafenib)—as a first treatment for 31 people with advanced bile duct cancer that couldn't be removed by surgery. The goal was to see how many patients' tumors shrank and how long they lived without the cancer growing. Researchers also tracked side effects. The study is complete, but results are not yet published.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hepatic arterial infusion chemotherapy, tislelizumab, and regorafenib
What this could lead to
If this combination works, it could offer a new first-line treatment option for people with advanced bile duct cancer, potentially shrinking tumors and extending life.
What could go wrong
This is a small, single-center, single-arm phase II trial with only 31 participants, so results may not apply broadly. The combination also carries risks of side effects from chemotherapy, immunotherapy, and targeted drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China